{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:28:02Z","timestamp":1764091682565,"version":"3.45.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1741","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved Vizz (Lenz Therapeutics), a 1.44% ophthalmic solution of the cholinergic agonist aceclidine, for treatment of presbyopia in adults. Aceclidine has been available in the EU for years for treatment of open-angle glaucoma.<\/jats:p>","DOI":"10.58347\/tml.2025.1741a","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:24:03Z","timestamp":1764091443000},"page":"177-178","source":"Crossref","is-referenced-by-count":0,"title":["Aceclidine (Vizz) for Presbyopia"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2025,11,10]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:24:03Z","timestamp":1764091443000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1741a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":0,"journal-issue":{"issue":"1741","published-online":{"date-parts":[[2025,11,10]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1741a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}